Clinical Trial Update: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

Phase 3 trial updating on efficacy, safety, and tolerability of AVP-786 for agitation in dementia of the Alzheimer's type (Alzheimer's disease-related agitation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation in Dementia
• Alzheimer Disease

Drugs mentioned

• AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Agitation in Participants With Dementia of the Alzheimer's Type | Phase 3 | Status: COMPLETED | Results posted: 2022-09-09